Alzamend Neuro Inc
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $52.55 million
- Book Value:
- Revenue TTM:
- Operating Margin TTM:
- Gross Profit TTM:
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
Alzamend Neuro Inc had its IPO on 2021-06-15 under the ticker symbol ALZN.
The company operates in the Healthcare sector and Biotechnology industry. Alzamend Neuro Inc has a staff strength of 4 employees.
Shares of Alzamend Neuro Inc opened at $0.38 at the start of the last trading session i.e. 2023-03-21.
The stocks traded within a range of $0.38 - $0.43, and closed at $0.42.
This is a +13.51% increase from the previous day's closing price.
A total volume of 361,971 shares were traded at the close of the day’s session.
In the last one week, shares of Alzamend Neuro Inc have slipped by -17.81%.
Alzamend Neuro Inc's Key Ratios
Alzamend Neuro Inc has a market cap of $52.55 million, indicating a price to book ratio of 11.6318 and a price to sales ratio of 0.
In the last 12-months Alzamend Neuro Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-12315986. The EBITDA ratio measures Alzamend Neuro Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Alzamend Neuro Inc’s operating margin was 0% while its return on assets stood at -63.04% with a return of equity of -115.43%.
In Q3.3333333333333, Alzamend Neuro Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Alzamend Neuro Inc’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-0.13 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Alzamend Neuro Inc’s profitability.
Alzamend Neuro Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -7.0897. Its price to sales ratio in the trailing 12-months stood at 0.
Alzamend Neuro Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $10.42 million
- Total Liabilities
- $1.64 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
Alzamend Neuro Inc ended 2023 with $10.42 million in total assets and $0 in total liabilities. Its intangible assets were valued at $10.42 million while shareholder equity stood at $8.79 million.
Alzamend Neuro Inc ended 2023 with $0 in deferred long-term liabilities, $1.64 million in other current liabilities, 9549.00 in common stock, $-35341560.00 in retained earnings and $0 in goodwill. Its cash balance stood at $9.18 million and cash and short-term investments were $9.18 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Alzamend Neuro Inc’s total current assets stands at $10.33 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $648119.00 and inventory worth $0.
In 2023, Alzamend Neuro Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Alzamend Neuro Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
Alzamend Neuro Inc stock is currently trading at $0.42 per share. It touched a 52-week high of $1.5 and a 52-week low of $1.5. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $0.58 and 200-day moving average was $0.91 The short ratio stood at 3.23 indicating a short percent outstanding of 0%.
Around 4166.5% of the company’s stock are held by insiders while 723.6% are held by institutions.
Frequently Asked Questions About Alzamend Neuro Inc
Similar Industry Stocks (Biotechnology)
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company’s pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.